TOP Investment Portfolio Heartseed Inc.
Life Science & Agritech

Heartseed Inc.

CEO, Keiichi Fukuda
Unlocking the potential of iPSCs


Heartseed is a biotech that is pioneering a completely new treatment for heart failure, which had previously only been treated by transplantation, with an approach of practical use of iPSC-based therapy. No matter how innovative the technology is, it is meaningless if it is a “special treatment” available only to a limited number of people. What we are aiming for is a “common treatment” that anyone can easily receive at any time.
As a result of bringing together a wide range of human resources and knowledge, and continuing to take on various challenges, we have overcome many challenges in the practical application of iPS cell-based medicine, and have developed original technologies for the stable manufacturing of large numbers of high-quality cardiomyocytes. We have also developed an original device to deliver the cardiomyocytes to the patient's heart.
Now, we are opening the door to a completely new treatment for heart failure that requires no special equipment, no overseas travel, and no search for donors, and even regenerative medicine as an emerging industry. We would like to connect the hearts of Heartseed team, partners, and patients facing treatment for heart failure, and also to connect as many lives as possible that can be saved to the future. With this belief, we will continue to move forward.


The founder has been a world leader in research on cardiac regeneration, including the world's first successful differentiation of cardiomyocytes from other cells. In 2015, when the technology development for practical use was complete, he established Heartseed. The company was named Heartseed because cardiomyocyte spheroids transplanted into the heart resemble the seeds of the heartseed, an ornamental plant, and in the hope that the spheroids will become save the heart failure patients as “heart seed”.


Our lead pipeline, iPS cell-derived cardiomyocyte spheroids HS-001, is expected to generate contractility directly in the heart through a mechanism of action called "remuscularization," in which transplanted cardiomyocyte spheroids are engrafted in the patient's heart, beat in synchrony and expected to generate direct contractile force.
The purity of cardiomyocytes and the engraftment rate are important to achieve this, and our strength lies in our many proprietary technologies, including technology to purify only cardiomyocytes and to increase the engraftment rate by spheroid formation through years of technological development.

The Artcomplex Center of Tokyo #302, 12-9, Daikyo-cho, Shinjuku-ku, Tokyo 160-0015, JAPAN


Sign up for UTokyo IPC news